Richard D. Carvajal
Columbia University in the City of New York
H-index: 69
North America-United States
Top articles of Richard D. Carvajal
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies | Oncoimmunology | Chia-Chi Lin Elena Garralda Patrick Schöffski David S Hong Lillian L Siu | 2024/12/31 |
Updates in the Management of Uveal Melanoma | Mali Barbi Richard D Carvajal Craig E Devoe | 2024/3/1 | |
Non-cutaneous melanoma: new therapeutic insights | Frontiers in Oncology | Ernesto Rossi Richard D Carvajal | 2024/1/17 |
Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials: A Systematic Review | Sheila Shaigany Nicole Mastacouris Rachel Tannenbaum Andrew Strunk Christopher Luan | 2024 | |
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma | Frontiers in Oncology | Sebastian Bauer James Larkin F Stephen Hodi Frank Stephen Ellen HW Kapiteijn | 2023/6/9 |
Scoping review of genetic databases for rare dermatologic diseases: opportunity for artificial intelligence and machine learning | Celine M Schreidah George Bingham Reynolds Lauren M Fahmy Richard D Carvajal Maarten H Vermeer | 2023/9/1 | |
1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial | Sapna P Patel Richard Carvajal Kamaneh Montazeri Sunil Reddy Jose Lutzky | 2023/11/1 | |
Kinetics of RTK activation determine ERK signaling dynamics and resistance to BRAF and MEK inhibitors | Cancer Research | Sungsoo Kim Richard Carvajal Minah Kim Hee Won Yang | 2023/4/4 |
Abstract CT223: Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM) | Cancer Research | Joseph J Sacco Richard D Carvajal Marcus O Butler Alexander N Shoushtari Jessica C Hassel | 2023/4/14 |
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Journal of Clinical Oncology | Suzanne L Topalian Mario Sznol David F McDermott Harriet M Kluger Richard D Carvajal | 2023/2/10 |
A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies | Cancer discovery | Prabhjot S Mundi Filemon S Dela Cruz Adina Grunn Daniel Diolaiti Audrey Mauguen | 2023/6/2 |
Diversifying Eligibility to Enhance Real-World Results | Fatima Fayyaz Richard D Carvajal Craig E Devoe | 2023/8/10 | |
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA) | Alexander Z Wei Lanyi N Chen Marlana Orloff Charlotte E Ariyan Maryam Asgari | 2023/11 | |
Abstract CT253: Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with nectin-4 associated advanced malignancies | Cancer Research | Thomas R Evans Afshin Dowlati Juanita S Lopez Mohammed M Milhem Jordi Rodón Ahnert | 2023/4/14 |
Multicenter phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification | Journal of Clinical Oncology | Siqing Fu Shuyang Yao Yuan Yuan Rebecca A Previs Anthony D Elias | 2023/3/20 |
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma | Dermatology Online Journal | Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro | 2023 |
ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma. | Jeffrey S Weber Richard D Carvajal Inderjit Mehmi Seung Tae Kim Miso Kim | 2023/6/1 | |
Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond | Annals of Translational Medicine | Lanyi Nora Chen Richard D Carvajal | 2023/8/8 |
1081O ctDNA reduction and clinical efficacy of the darovasertib+ crizotinib (daro+ crizo) combination in metastatic uveal melanoma (MUM) | Annals of Oncology | M Mckean B Chmielowski MO Butler R Carvajal J Rodon | 2023/10/1 |
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma | British journal of cancer | S Piperno-Neumann MS Carlino V Boni D Loirat FM Speetjens | 2023/4/6 |
Co-Authors
